Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135641 | 0.91 | MEN1 (0.33) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL6024752 | 0.83 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL28299078 | 0.82 | CES2 (0.42) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL4706953 | 0.79 | MEN1 (0.33) | FFAR3ALDH1A1MEN1CYP1A2THRB | |
| SCHEMBL15442979 | 0.76 | — | — | |
| SCHEMBL28101100 | 0.75 | LMNA (0.34) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5709860 | 0.75 | FFAR3 (0.32) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11124099 | 0.75 | ALDH1A1 (0.32) | ALDH1A1CYP1A2KMT2AACLYHSD17B10 | |
| SCHEMBL11124088 | 0.75 | ALDH1A1 (0.32) | ALDH1A1CYP1A2KMT2AACLYHSD17B10 | |
| SCHEMBL6154156 | 0.74 | CES2 (0.40) | ALDH1A1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051735-A2 | CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AS WELL AS THEIR USE IN TREATING CNS DISORDERS | Ramot, at Tel Aviv University Ltd. (IL) | 2009-04-29 | — | — | EP | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| WO-2008062471-A2 | A MILD METHOD FOR THE PRODUCTION OF DI-N-PROPYLACETIC ACID (VALPROIC ACID) | CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008010223-A2 | CONJUGATES COMPRISING A PSYCHOTROPIC DRUG OR A GABA AGONIST AND AN ORGANIC ACID AND THEIR USE IN TREATING PAIN AND OTHER CNS DISORDERS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | FFAR3 830/4885HDAC3 2865/4885HDAC1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.